

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

| | | | |
|--|--|---|---------------------------------------|
| <hr/> | |) | |
| JANSSEN BIOTECH, INC. and | |) | |
| NEW YORK UNIVERSITY | |) | |
| Plaintiffs, | |) | |
| | |) | |
| v. | |) | Civil Action No. 1:15-cv-10698 |
| | |) | |
| CELLTRION HEALTHCARE CO., LTD., | |) | |
| CELLTRION, INC., and | |) | |
| HOSPIRA, INC. | |) | |
| Defendants. | |) | |
| <hr/> | |) | |


mw **PROPOSED ORDER TO AMEND THE PROTECTIVE ORDER**

This Court, having granted Plaintiffs Janssen Biotech, Inc.’s and New York University’s Motion to Modify the Protective Order, hereby ORDERS the following amendment (“a.”) to Paragraph 9 of the Protective Order’s section regarding “Use and Control of the Confidential Information”:

a. Plaintiffs may use Confidential Information obtained in this litigation for the purpose of instituting and prosecuting other proceedings against Celltrion Healthcare Co., Ltd., Celltrion, Inc., Hospira, Inc., and/or HyClone Laboratories Inc. relating to U.S. Patent No. 7,598,083 so long as any Confidential Information is protected by a protective order in any such proceeding or filed under seal. Defendants reserve all rights to respond to any such new proceedings as deemed appropriate.

IT IS SO ORDERED.

Dated: May 31, 2016



Hon. Mark L. Wolf

United States District Court Judge